title: Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology.
abstract: The objective was to collect recent data on the antibiotic susceptibility of clinically significant anaerobes in Belgium. A total of 333 anaerobic clinical isolates from various body sites were prospectively collected between 2005 and 2007 at two tertiary care hospitals in Belgium. The minimal inhibitory concentrations (MICs) were determined using the E-test method for nine anti-anaerobic antibiotics. Sixty-one percent of the isolates were beta-lactamase producers, which explains the poor activity of penicillin. Amoxicillin/clavulanic acid, piperacillin/tazobactam, metronidazole and meropenem were very active against most anaerobes, but around 10% of the Bacteroides fragilis group strains were non-susceptible to the two beta-lactam/beta-lactamase inhibitors. No resistance was observed to metronidazole, while 3% of the Bacteroides spp. had decreased susceptibility to meropenem (MIC > or = 4 mg/L). Cefoxitin, clindamycin and moxifloxacin were less active, with 33%, 52% and 57% of the B. fragilis group being non-susceptible respectively. Tigecycline showed consistently good activity against most anaerobes with MIC(50) and MIC(90) of 0.25 and 2 mg/L. Metronidazole, amoxicillin/clavulanate, piperacillin/tazobactam and meropenem remain good empirical choices when anaerobes are expected in our setting. Because of the occurrence of resistance to most classes of current anti-anaerobic antibiotics, it is recommended that the antimicrobial resistance patterns be monitored regularly in order to guide empirical therapy.
authors.affiliation: Department of Clinical Microbiology, Cliniques Universitaires de Mont-Godinne, 5530 Yvoir, Belgium. youri.glupczynski@skynet.be
authors.forename: Y
authors.initials: Y
authors.lastname: Glupczynski
authors.forename: C
authors.initials: C
authors.lastname: Berhin
authors.forename: H
authors.initials: H
authors.lastname: Nizet
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology*; D001530:Belgium; D006801:Humans; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D001618:beta-Lactamases
references.citation: Clin Infect Dis. 2000 Jun;30(6):870-6
references.pmid: 10852736
references.citation: Lancet. 2005 Feb 12-18;365(9459):579-87
references.pmid: 15708101
references.citation: Clin Infect Dis. 1998 Jun;26(6):1413-7
references.pmid: 9636872
references.citation: Clin Microbiol Infect. 2003 Jun;9(6):475-88
references.pmid: 12848722
references.citation: Clin Microbiol Infect. 2005 Oct;11(10):820-4
references.pmid: 16153256
references.citation: J Antimicrob Chemother. 2006 May;57(5):992-8
references.pmid: 16507560
references.citation: J Antimicrob Chemother. 2005 Aug;56(2):349-52
references.pmid: 15951353
references.citation: J Antimicrob Chemother. 2008 Jul;62(1):137-41
references.pmid: 18385145
references.citation: J Antimicrob Chemother. 2002 Dec;50(6):1055-7
references.pmid: 12461033
references.citation: J Antimicrob Chemother. 2007 Jan;59(1):132-9
references.pmid: 17095529
references.citation: Antimicrob Agents Chemother. 2007 May;51(5):1649-55
references.pmid: 17283189
references.citation: Diagn Microbiol Infect Dis. 1995 Jul;22(3):279-84
references.pmid: 8565417
references.citation: J Clin Microbiol. 2007 Aug;45(8):2474-9
references.pmid: 17522277
references.citation: J Clin Microbiol. 1991 Oct;29(10):2197-203
references.pmid: 1939571